• <button id="lp3sr"></button>
  • Graduation season | Abcam RabMab? unprecedented price

    Tens of thousands of experts, recombinant RabMab®,

    have never been discounted today,

    the opportunity is rare, hurry to place an order!

    The second wave of Abcam's 20th Anniversary is in full swing. In order to give back to the new and old users who have long supported Abcam, the RabMAb® (abcam patented rabbit monoclonal antibody) will be reorganized as low as 65% (except for 10ul in small packages)! The decline has never been seen before! Help accelerate your scientific discovery!


    Buy unlimited times, only within 24 days:


    This is a big promotion, never miss it ?。?!

    What is RabMAb®?

    RabMAb®: a rabbit monoclonal antibody, a monoclonal antibody produced by high-quality rabbit-derived hybridoma cells, is the only system in the world that uses fusion methods to develop rabbit monoclonal antibodies. It was acquired by Abcam in 2012 and the technology patent was also included in Abcam.

    RabMAb® technology advantage

    RabMAb® technology is a unique and proprietary method for developing monoclonal antibodies in rabbit sources rather than using traditional methods to develop from murine sources. The antibodies obtained in this manner have high affinity for polyclonal antibodies and specificity for monoclonal antibodies.

    Antibodies produced using RabMAb® technology have better antigen recognition capabilities than traditional murine antibodies. This is caused by the uniqueness of the rabbit immune system. Through extensive research, rabbits have been able to produce more specific and sensitive antibodies than rodents and other rodents.

    The rationale for preparing antibodies using RabMAb® technology is identical to that of mouse monoclonal antibodies. A proprietary rabbit fusion partner cell can be fused to rabbit B cells to produce a rabbit hybridoma cell. Hybridoma cells are then screened to select clones with specific and sensitive antigen recognition capabilities, and antibodies are identified using a variety of methods.

    Why use a rabbit system to prepare antibodies?

    Compared to other species, such as mice, rats, and chickens, rabbits have a unique immune system. Rabbits have large B cell repertoires, which means they produce a very diverse range of antibodies.

    The affinity optimization mechanism of the rabbit immune system is more effective than mice and other rodents. Rabbits can be used to produce these high-affinity antibodies, even for antigens that are not immunogenic in mice. On average, the affinity of a rabbit monoclonal antibody to a target antigen is 10-100 times that of a mouse monoclonal antibody.

    Due to the larger and more diverse B cell reaction pool, rabbit antibodies are also advantageous in distinguishing subtle differences such as epitope variation (eg, modification), mutations, and conformational changes. The RabMAb® antibody combines the best properties of a monoclonal antibody with the optimal properties of a rabbit polyclonal antibody with several advantages:

    • Identify multiple epitopes

    • High affinity and specificity

    • Cross-species reactivity, which can be studied in more common rodent models – no need to use surrogate antibodies in preclinical trials.

    • For a variety of applications, each RabMAb primary antibody was tested in a variety of applications (WB, IHC, ICC/IF, IP, and flow cytometry and multiple species (human, mouse, and rat) before marketing.

    1. Find RabMab antibodies

    Please note: When searching for products on the official website, only antibodies labeled RabMAb will participate in this activity. Please look for this logo as follows:

    2. Hot Products List

    The following is a list of hot products for your reference!

    This event is hosted by Abcam and Abcam reserves the right to interpret this event.

    Zhongyuan is an authorized agent of Abcam.

    If you have any questions, please call the toll-free service.


    If you have any comments or suggestions on our services, please send them to the following email address.